Cystic echinococcosis therapy: Albendazole-loaded lipid nanocapsules enhance the oral bioavailability and efficacy in experimentally infected mice
Therapeutic failures attributed to medical management of cystic echinococcosis (CE) with albendazole (ABZ) have been primarily linked to the poor drug absorption rate resulting in low drug level in plasma and hydatid cysts. Lipid nanocapsules (LNCs) represent nanocarriers designed to encapsulate lip...
Guardado en:
| Publicado: |
2015
|
|---|---|
| Materias: | |
| Acceso en línea: | https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_0001706X_v152_n_p185_Pensel http://hdl.handle.net/20.500.12110/paper_0001706X_v152_n_p185_Pensel |
| Aporte de: |
| id |
paper:paper_0001706X_v152_n_p185_Pensel |
|---|---|
| record_format |
dspace |
| spelling |
paper:paper_0001706X_v152_n_p185_Pensel2023-06-08T14:21:16Z Cystic echinococcosis therapy: Albendazole-loaded lipid nanocapsules enhance the oral bioavailability and efficacy in experimentally infected mice Albendazole Cystic echinococcosis Echinococcus granulosus Lipid nanocapsules albendazole lipid nanocapsule nanocapsule unclassified drug albendazole anthelmintic agent lipid bioavailability concentration (composition) drug lipid medical geography parasitic disease rodent animal experiment animal model area under the curve Article controlled study drug bioavailability drug blood level drug dosage form comparison drug efficacy drug exposure drug formulation echinococcosis female in vitro study maximum plasma concentration mouse nanoencapsulation nonhuman time to maximum plasma concentration animal bioavailability drug delivery system echinococcosis Echinococcus granulosus medicinal chemistry oral drug administration Animalia Echinococcus granulosus Mus Administration, Oral Albendazole Animals Anthelmintics Biological Availability Chemistry, Pharmaceutical Drug Delivery Systems Echinococcosis Echinococcus granulosus Female Lipids Mice Nanocapsules Therapeutic failures attributed to medical management of cystic echinococcosis (CE) with albendazole (ABZ) have been primarily linked to the poor drug absorption rate resulting in low drug level in plasma and hydatid cysts. Lipid nanocapsules (LNCs) represent nanocarriers designed to encapsulate lipophilic drugs, such as ABZ. The goals of the current work were: (i) to characterize the plasma and cyst drug exposure after the administration of ABZ as ABZ-LNCs or ABZ suspension (ABZ-SUSP) in mice infected with Echinococcus granulosus, and ii) to compare the clinical efficacies of both ABZ formulations. Enhanced ABZ sulphoxide (ABZ-SO) concentration profiles were obtained in plasma and cysts from ABZ-LNC treated animals. ABZSO exposure (AUC0-LOQ) was significantly higher in plasma and cyst after the ABZ-LNC treatments, both orally and subcutaneously, compared to that observed after oral administration of ABZ-SUSP. Additionally, ABZSO concentrations measured in cysts from ABZ-LNC treated mice were 1.7-fold higher than those detected in plasma. This enhanced drug availability correlated with an increased efficacy against secondary CE in mice observed for the ABZ-LNCs, while ABZ-SUSP did not reach differences with the untreated control group. This new pharmacotechnically-based strategy could be a potential alternative to improve the treatment of human CE. © 2015 Elsevier B.V. 2015 https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_0001706X_v152_n_p185_Pensel http://hdl.handle.net/20.500.12110/paper_0001706X_v152_n_p185_Pensel |
| institution |
Universidad de Buenos Aires |
| institution_str |
I-28 |
| repository_str |
R-134 |
| collection |
Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) |
| topic |
Albendazole Cystic echinococcosis Echinococcus granulosus Lipid nanocapsules albendazole lipid nanocapsule nanocapsule unclassified drug albendazole anthelmintic agent lipid bioavailability concentration (composition) drug lipid medical geography parasitic disease rodent animal experiment animal model area under the curve Article controlled study drug bioavailability drug blood level drug dosage form comparison drug efficacy drug exposure drug formulation echinococcosis female in vitro study maximum plasma concentration mouse nanoencapsulation nonhuman time to maximum plasma concentration animal bioavailability drug delivery system echinococcosis Echinococcus granulosus medicinal chemistry oral drug administration Animalia Echinococcus granulosus Mus Administration, Oral Albendazole Animals Anthelmintics Biological Availability Chemistry, Pharmaceutical Drug Delivery Systems Echinococcosis Echinococcus granulosus Female Lipids Mice Nanocapsules |
| spellingShingle |
Albendazole Cystic echinococcosis Echinococcus granulosus Lipid nanocapsules albendazole lipid nanocapsule nanocapsule unclassified drug albendazole anthelmintic agent lipid bioavailability concentration (composition) drug lipid medical geography parasitic disease rodent animal experiment animal model area under the curve Article controlled study drug bioavailability drug blood level drug dosage form comparison drug efficacy drug exposure drug formulation echinococcosis female in vitro study maximum plasma concentration mouse nanoencapsulation nonhuman time to maximum plasma concentration animal bioavailability drug delivery system echinococcosis Echinococcus granulosus medicinal chemistry oral drug administration Animalia Echinococcus granulosus Mus Administration, Oral Albendazole Animals Anthelmintics Biological Availability Chemistry, Pharmaceutical Drug Delivery Systems Echinococcosis Echinococcus granulosus Female Lipids Mice Nanocapsules Cystic echinococcosis therapy: Albendazole-loaded lipid nanocapsules enhance the oral bioavailability and efficacy in experimentally infected mice |
| topic_facet |
Albendazole Cystic echinococcosis Echinococcus granulosus Lipid nanocapsules albendazole lipid nanocapsule nanocapsule unclassified drug albendazole anthelmintic agent lipid bioavailability concentration (composition) drug lipid medical geography parasitic disease rodent animal experiment animal model area under the curve Article controlled study drug bioavailability drug blood level drug dosage form comparison drug efficacy drug exposure drug formulation echinococcosis female in vitro study maximum plasma concentration mouse nanoencapsulation nonhuman time to maximum plasma concentration animal bioavailability drug delivery system echinococcosis Echinococcus granulosus medicinal chemistry oral drug administration Animalia Echinococcus granulosus Mus Administration, Oral Albendazole Animals Anthelmintics Biological Availability Chemistry, Pharmaceutical Drug Delivery Systems Echinococcosis Echinococcus granulosus Female Lipids Mice Nanocapsules |
| description |
Therapeutic failures attributed to medical management of cystic echinococcosis (CE) with albendazole (ABZ) have been primarily linked to the poor drug absorption rate resulting in low drug level in plasma and hydatid cysts. Lipid nanocapsules (LNCs) represent nanocarriers designed to encapsulate lipophilic drugs, such as ABZ. The goals of the current work were: (i) to characterize the plasma and cyst drug exposure after the administration of ABZ as ABZ-LNCs or ABZ suspension (ABZ-SUSP) in mice infected with Echinococcus granulosus, and ii) to compare the clinical efficacies of both ABZ formulations. Enhanced ABZ sulphoxide (ABZ-SO) concentration profiles were obtained in plasma and cysts from ABZ-LNC treated animals. ABZSO exposure (AUC0-LOQ) was significantly higher in plasma and cyst after the ABZ-LNC treatments, both orally and subcutaneously, compared to that observed after oral administration of ABZ-SUSP. Additionally, ABZSO concentrations measured in cysts from ABZ-LNC treated mice were 1.7-fold higher than those detected in plasma. This enhanced drug availability correlated with an increased efficacy against secondary CE in mice observed for the ABZ-LNCs, while ABZ-SUSP did not reach differences with the untreated control group. This new pharmacotechnically-based strategy could be a potential alternative to improve the treatment of human CE. © 2015 Elsevier B.V. |
| title |
Cystic echinococcosis therapy: Albendazole-loaded lipid nanocapsules enhance the oral bioavailability and efficacy in experimentally infected mice |
| title_short |
Cystic echinococcosis therapy: Albendazole-loaded lipid nanocapsules enhance the oral bioavailability and efficacy in experimentally infected mice |
| title_full |
Cystic echinococcosis therapy: Albendazole-loaded lipid nanocapsules enhance the oral bioavailability and efficacy in experimentally infected mice |
| title_fullStr |
Cystic echinococcosis therapy: Albendazole-loaded lipid nanocapsules enhance the oral bioavailability and efficacy in experimentally infected mice |
| title_full_unstemmed |
Cystic echinococcosis therapy: Albendazole-loaded lipid nanocapsules enhance the oral bioavailability and efficacy in experimentally infected mice |
| title_sort |
cystic echinococcosis therapy: albendazole-loaded lipid nanocapsules enhance the oral bioavailability and efficacy in experimentally infected mice |
| publishDate |
2015 |
| url |
https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_0001706X_v152_n_p185_Pensel http://hdl.handle.net/20.500.12110/paper_0001706X_v152_n_p185_Pensel |
| _version_ |
1768544016819814400 |